Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

Blueprint Medicines Corporation (NASDAQ: BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...